Showing results (1-10 of 20) with videos related to
Sort By:
Pageof 2
Biochimie|August 16, 2011
Lipids, curvature stress, and the action of lipid prodrugs: free fatty acids and lysolipid enhancement of drug transport across liposomal membranesHenrik Jespersen, Jonas H Andersen, Henrik J Ditzel, et al.Case Reports in Oncology|October 30, 2024
Delayed Distant Recurrence of a Uveal Melanoma 4 Decades after EnucleationNils A Eide, Agate Noer, Henrik Jespersen, et al.Anti-Cancer Drugs|June 19, 2010
Effect of free fatty acids and lysolipids on cellular uptake of doxorubicin in human breast cancer cell linesNicolaj Rasmussen, Jonas H Andersen, Henrik Jespersen, et al.Acta Oncologica (Stockholm, Sweden)|June 2, 2019
Real-world data on PD-1 inhibitor therapy in metastatic melanomaAnna Arheden, Joanna Skalenius, Sara Bjursten, et al.BJC Reports|April 11, 2025
Immune checkpoint inhibitor therapy is associated with a decreased risk of developing melanoma brain metastasesAnna Fager, Matilda Samuelsson, Roger Olofsson Bagge, et al.Melanoma Research|November 10, 2021
Epigenetic therapy to enhance therapeutic effects of PD-1 inhibition in therapy-resistant melanomaVasu R Sah, Joakim Karlsson, Henrik Jespersen, et al.The British Journal of Ophthalmology|April 16, 2026
Trends in incidence and survival for uveal melanoma in Norway, 1993-2021Nils Leitzinger, Ragnhild S Falk, Henrik Jespersen, et al.Journal for Immunotherapy of Cancer|July 3, 2021
Early rise in brain damage markers and high ICOS expression in CD4+ and CD8+ T cells during checkpoint inhibitor-induced encephalomyelitisSara Bjursten, Ankur Pandita, Zhiyuan Zhao, et al.Nature Communications|September 29, 2017
Clinical responses to adoptive T-cell transfer can be modeled in an autologous immune-humanized mouse modelHenrik Jespersen, Mattias F Lindberg, Marco Donia, et al.Pageof 2